
Novo Nordisk protects US patients with legal wins against compounders, including ruling that permanently prohibits compounding pharmacy from selling illegitimate, knockoff Wegovy® or Ozempic®
Federal court ruling leaves in place FDA's decision resolving the shortage of Wegovy® and Ozempic®, which are fully available nationwide, and ends the grace period for pharmacies to make or sell compounded 'versions' of these medicines
Separate federal court ruling permanently bars MediOak Pharmacy LLC from marketing or selling illegitimate 'semaglutide' drugs
Legal wins build on 111 lawsuits filed by Novo Nordisk across 32 states against entities unlawfully marketing and selling compounded 'semaglutide' drugs, helping safeguard Americans from knockoffs made with unsafe or illicit foreign API
Novo Nordisk is dedicated to dialogue with companies to support patient access to authentic, FDA-approved Wegovy® under the care of a licensed healthcare professional
PLAINSBORO, N.J., April 25, 2025 /PRNewswire/ — Yesterday, a Texas federal court ruled in favor of Novo Nordisk and FDA, denying a compounding trade association's motion to freeze the FDA's decision to end the shortage of semaglutide injectable medicines. The court's ruling left in place FDA's prior determination that all doses of Wegovy® and Ozempic® are fully available nationwide and that Novo Nordisk's supply of these FDA-approved medicines is meeting or exceeding current and projected nationwide patient demand. With the FDA's resolution of the shortage of Ozempic® and Wegovy®, as left in place by this court ruling, it is illegal under US compounding laws to make or sell knockoff 'semaglutide drugs,' with rare exceptions.
In light of the court's decision today, FDA may immediately take action against 503A pharmacies compounding knockoff versions of Novo Nordisk's FDA-approved semaglutide medicines. The ruling also means the grace period for 503B outsourcing facilities to compound semaglutide injectable drugs will expire on May 22, 2025, and FDA may take enforcement action against these entities after that date.
This latest win on behalf of patients follows another key decision by the District Court for the Southern District of Texas, where a federal judge entered a final judgment and permanent injunction in favor of Novo Nordisk, against a 503A pharmacy, MediOak Pharmacy LLC, permanently prohibiting them from marketing or selling compounded 'semaglutide' knockoff drugs.
'We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage of Wegovy® and Ozempic® is resolved,' said Steve Benz, Corporate Vice President, Legal and US General Counsel, Novo Nordisk. 'FDA's determination was based on a thorough review of Novo Nordisk's stable and growing supply of these important FDA-approved medicines. With the end of the shortage of Wegovy® and Ozempic®, no patient should have to be exposed to unsafe, inauthentic 'semaglutide' drugs. Patient safety remains a top priority for Novo Nordisk and the extensive nationwide legal actions we have taken to protect Americans from the health risks posed by illegitimate 'semaglutide' drugs are working. We will continue driving these actions forward and escalate our efforts as necessary, while closely engaging with regulators and law enforcement.'
Illicit foreign API in compounded 'semaglutide'
The resolution of the semaglutide injection shortage and the court's ruling also help protect patients against the proliferation of unsafe and unlawful drugs compounded using imports of synthetic 'semaglutide' active pharmaceutical ingredients (APIs) that are manufactured overseas. A recently published Brookings Institute report titled The Wild East of semaglutide confirms that many US patients are being exposed to unsafe and illegal imports of synthetic semaglutide APIs from China. The report highlights numerous issues, including that manufacturers of chemically synthesized semaglutide API have no external reference standard for quality and instead determine specifications themselves. It also demonstrated that three Chinese firms are responsible for 20% of the reported quantity of semaglutide imported into the US between March 2023 and September 2024 and have never been inspected by FDA, as of September 2024. Additionally, another three Chinese firms, responsible for nearly 45% of reported imported volume during this 18-month period, were cited during their latest FDA inspection for current good manufacturing practice violations. As this report shows, the quality of API originating from China and used in compounded 'semaglutide' in the US cannot be assured and puts patients at serious risk. Novo Nordisk does not directly or indirectly distribute the semaglutide API in its FDA-approved medicines to any entity for use in compounding.
Novo Nordisk federal lawsuits filed to date
To date, the company has filed 111 lawsuits in federal courts across 32 states against entities unlawfully marketing and selling compounded 'semaglutide,' including drugs that pose significant risks to patient safety due to high levels of impurities (as high as 33%) or misbranded due to inaccurately labeled strengths.
Many of these courts have already issued injunctions permanently prohibiting these entities from the unlawful marketing and sales of compounded drugs:
Earlier this year, a federal court in Delaware entered an $8.5 million default judgment in Novo Nordisk's favor against a business for willfully and falsely claiming that their compounded 'semaglutide' drugs were equivalent to Ozempic® or used the same active ingredient as FDA-approved Ozempic®. Another federal court permanently prohibited a compounding pharmacy in Tennessee, Midtown Express, from marketing or selling knockoff 'semaglutide' after Novo Nordisk sued it for selling a drug that contained no semaglutide at all.
In another case, a federal court granted a default judgement against an online marketer sued by Novo Nordisk, ending its unlawful practice of selling compounded 'semaglutide' directly to consumers without a prescription or instructions for use, misleadingly labeling it as for 'Research Use Only.'
Dozens of other courts have entered permanent injunctions against the entities sued by Novo Nordisk, permanently forbidding them from falsely claiming that knockoff 'semaglutide' drugs: (1) are genuine Novo Nordisk medicines; (2) are approved by FDA, are authentic generic medicines, or are safe and effective; (3) achieve any therapeutic result or are safe or effective based on the clinical trial results for Novo Nordisk's approved medicines; and (4) contain semaglutide that has been approved by FDA, is supplied by Novo Nordisk, or is the same as that in Wegovy® and Ozempic®.
The court orders also direct businesses to correct misimpressions among patients that were caused by the defendants' deceptive practices. This includes posting prominent disclosures in marketing and advertising to make clear that the unapproved compounded drugs have not been reviewed or approved by the FDA, that the manufacturing processes used to make the drugs are not FDA-reviewed, and that actual FDA-approved semaglutide medicines are available.
Actions taken by third parties to warn the public
Novo Nordisk supports the actions that have already been taken by law enforcement to protect patients from illegal marketing and sales of compounded drugs. A bipartisan coalition of 38 state Attorneys General have called on the FDA to take swift action against compounding pharmacies that 'cut corners in pursuit of a quick profit' and sell knockoff drugs that could lead to 'serious public health issues.' The Ohio Attorney General recently issued a press release about letters it sent to 14 entities warning them to stop deceiving patients into believing that compounded drugs are approved by the FDA or have been reviewed for safety, effectiveness, or quality and declaring that patients 'deserve clear and accurate information about the medication they're putting in their bodies.' Similarly, in December 2024, the Illinois Attorney General issued cease-and-desist letters to five Chicagoland med spas advertising name brand medications like Wegovy® and Ozempic® but 'instead offering unapproved versions of these products that may put people's health at risk.' In addition, over a dozen Attorneys General have issued statements discussing the dangers posed by knockoff 'semaglutide,' including North Carolina, South Carolina, and Tennessee.
The Federal Bureau of Investigation also recently warned the public about safety concerns related to fraudulent compounding practices associated with weight loss drugs, warning that '[s]ome healthcare providers are using compounded mixtures of unknown drugs that do not contain semaglutide, drugs with high levels of impurities, and unsafe or unapproved drugs.'
Novo Nordisk is continuing to actively address this issue through education, advocacy, and legal action, fighting on behalf of patients who deserve to know what they are injecting into their body.
For more information about Novo Nordisk's efforts to protect patients and ensure access to safe, effective FDA-approved treatments, visit semaglutide.com
About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at semaglutide.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
2 hours ago
- Malaysian Reserve
Newlyweds Say 'I Do' to Love, But 'I Don't' to Estate Planning: 42% of Couples Haven't Created One
New Survey from Trust & Will Finds Marriage Sparks Conversations About Legacy—But Many Delay Estate Planning for a Decade or More SAN DIEGO, June 9, 2025 /PRNewswire/ — Love is in the air this wedding season, but financial protection isn't. A new report from Trust & Will exposes a critical disconnect between love, life milestones, and long-term planning. Despite saying 'till death do us part,' 42% of married Americans have no estate plan whatsoever – leaving their spouses and families financially vulnerable. With over two million weddings expected for 2025 – with 225,000 expected in June alone and well over 600,000 in summer1 – the timing couldn't be more critical. Yet, the survey reveals that even marriage, one of life's most significant milestones, fails to prompt immediate action on estate planning. 'When I got married, my wife and I realized we had no will, no healthcare directive, nothing. It was a wake-up call,' said Cody Barbo, Co-founder and CEO of Trust & Will. 'That realization inspired the very foundation of this company. Marriage is about building a life together, and an estate plan is part of securing that life.' The national survey of 750 Americans (evenly split among single, engaged, and married respondents) uncovered deep gaps in awareness, confidence, and estate planning behavior. The Procrastination Problem: While married individuals are nearly 4x more likely than engaged couples to have a will (44% vs. 12%), nearly half still have no estate plan at all. Of those who do plan, 30% waited 9 years or more after marriage to act; 38% of engaged respondents say marriage motivated them to consider estate planning. Only 19% of married couples create an estate plan within their first four years together. Overcoming the Engagement Disconnect: 38% of engaged couples say marriage motivates them to consider estate planning, but only 12% actually have a will. 50% admit they lack basic estate planning knowledge. Only 15% have a healthcare directive, and 9% don't know what one is. 37% haven't even considered naming an executor or trustee for their estate. The Gender and Generational Divide Millennials and Gen Z show strong intent (40%+ plan to create estate plans within 5 years) but they face barriers like cost, time, and lack of understanding. Men are 3x more likely to have a trust than women. Women are more likely to feel overwhelmed by estate planning and 38% more likely to feel financially insecure. Despite 67% of respondents citing 'being overwhelmed' as their primary barrier, estate planning can be completed in hours. Without planning, surviving spouses can face: A lengthy and expensive probate process. Inability to make critical medical decisions. Freezing of financial accounts. Disputes among family members over assets. Potential tax issues. 'A wedding is more than a celebration, it's a pledge to protect one another,' said Barbo. 'Creating an estate plan is one of the most meaningful expressions of love. It offers your partner peace of mind, security, and the clarity that comes from knowing your wishes are understood and honored.' To read the full report, please visit: About Trust & WillFounded in 2017, Trust & Will is the leading digital estate planning platform in the U.S., trusted by over one million individuals and families. Our simple, secure, and attorney-approved online solutions help Americans easily create wills, trusts, healthcare directives, and other essential estate planning documents tailored to state-specific laws. With a focus on easy access and a guided experience, we're transforming how families plan for the future and protect their legacies. Our platform supports 20,000+ financial advisors, along with 150+ enterprise partners and financial institutions — including AARP, Fifth Third Bank, LPL Financial, UBS, and USAA. We empower professionals to integrate estate planning into their client services, enabling multi-generational wealth planning. With more than one million users and $100+ billion in self-reported estate assets, Trust & Will is redefining estate planning as a relationship-deepening driver of financial wellness. Recognized for innovation and leadership, Trust & Will has earned spots on the CNBC Disruptor 50, Inc. 5000, and Deloitte Technology Fast 500™ lists. Learn more at Media Contact: Mark LoCastro, Trust & Willpress@ 1 'Here Comes … A Lot of Couples Getting Married,' National Jeweler, June 29, 2022 [source URL]


Malaysian Reserve
14 hours ago
- Malaysian Reserve
5th BEYOND Expo 2025 Creates an Enduring Legacy for Asian Tech Innovation
A record number of exhibitors and unprecedented investor participation defined this year's success. New business matchmaking milestones further elevated BEYOND Expo 2025. Fund at First Pitch, Innovation Awards, Founder Stage and Founders Club Among Key Initiatives Supporting Entrepreneurs from across Asia. MACAO, June 9, 2025 /PRNewswire/ — The 5th BEYOND Expo concluded at The Venetian® Macao's Cotai with unprecedented momentum, cementing its role as a cornerstone for Asian tech innovation under the theme 'Empowering Asia, Bridging the World.' From inspiration by startups to wisdom shared by Alibaba Group's Chairman Joe Tsai, tech leaders and visionaries illustrated BEYOND Expo's commitment to supporting tech innovation in Asia. This year's BEYOND Expo attracted a record-breaking 25,000+ visitors, 800+ exhibitors, 300 media representatives, and over 800 investors, including more than 300 family offices and LPs, from over 120 countries — the highest numbers to date. Covering sectors from AI, Healthcare, Mobility, Property Tech, Clean Energy, Robotics, Fashion Tech, Sports Tech, to Web3, this year marked the largest and most content-rich BEYOND Expo to date. Beyond the breadth of industry focus, BEYOND Expo also deepened its commitment to regional collaboration through a series of forums spotlighting strategic markets such as Southeast Asia, Japan, the Middle East, Latin America, and Europe. This dual emphasis on sector innovation and regional opportunity positioned BEYOND Expo as one of the most prominent and impactful pan-Asian tech gatherings ever held. BEYOND Expo Co-Founder Dr. LU Gang said, 'This year there has been a tremendous energy around BEYOND Expo, fueled by Asia's rapid rise in frontier technologies and a greater desire for inter-Asian collaboration and cooperation. The products and solutions on display demonstrate just how much AI is transforming so many aspects of our lives, from the food we eat and the clothes we wear to how we interact with each other. Our ecosystem partners, including media, investors, incubators, and suppliers, are driving this momentum and nurturing next-generation technologies.' BEYOND Expo recognized some of these innovators by presenting 25 Innovation Awards and hosting competitions such as Fund at First Pitch (FAFP), which attracted 150 competitors. JumpStart Media Executive Chairman James Kwan chaired the 2025 FAFP finale, which featured three high profile investors as judges: Artest Management Group (AMG) Chairman, Metta World Peace; Gobi Partners Co-founder and Chairperson, Thomas Tsao, and Lingotto Innovation Managing Partner & Co-Head, Morgan Samet. BEYOND Expo Co-Founder Jason Ho added, 'The impact of BEYOND Expo 2025 extends beyond the event itself. It has matured into a year-round ecosystem with the BEYOND Global Network and BEYOND Founders Club, initiatives that support the global expansion of Asian tech companies and foster knowledge and resource sharing among entrepreneurs, driving technological advancements to address global challenges.' Most International Speaker Lineup and Dynamic Stage Experience in BEYOND's History During the three-day exhibition, BEYOND Expo delivered its most internationally diverse and intellectually stimulating content lineup ever. More than 300 speakers from across the globe, including Greater China, the United States, United Kingdom, Portugal, the Netherlands, Belgium, Brazil, Mexico, UAE, Singapore, Japan, South Korea, Thailand, Malaysia, Indonesia, Vietnam, Pakistan, and beyond, took the stage to share bold ideas and transformative insights. Seven thematic stages were strategically placed across the expo floor, offering an immersive and accessible experience for all attendees. From visionary keynotes to dynamic roundtables, these sessions spanned global trends and regional collaboration, across topics such as: Global Vision Summits: The BGlobal Summit, Global Investment Summit, Wealth Summit and Cross-Border E-commerce Ecosystem Forum explored how Asian innovators are scaling globally. Regional Collaboration Forums: Asia-Europe Tech Forum, Asia-Latam Tech Forum, ORIGIN Southeast Asia Conference, Japan Tech Forum, and the Zayed Sustainability Prize China Forum created rare opportunities for cross-regional partnerships and investment dialogues. Frontier Tech Spotlights: AI Summit, Web3 + AI Forum, Founders Talk, Transportation & Mobility Summit, Sports Tech Forum, Fashion Tech Forum, International Industrial Design Forum, and Gen Z Founder Forum brought cutting-edge conversations and industry innovation to the forefront. Women in Tech: The SheTech Summit championed greater representation and leadership for women in the tech ecosystem. This comprehensive summit program reinforced BEYOND Expo's status as a leading platform for driving innovation, collaboration, and growth in Asia's technology ecosystem. A Special Focus on Asia's Unicorn Founders The Opening Ceremony on May 21 convened some of the most influential minds in Asian tech to explore the theme 'What's Next?'. Among the featured speakers were Dr. Jian Wang, President of Zhejiang Lab and Founder of Alibaba Cloud; Carl Pei, Co-founder and CEO of Nothing; Dr. Burt Guo, CEO and Chief Scientist of Sichuan Aerofugia; Yuekai Zhao, Co-founder of Agile Robots SE; and Jingkang Liu, Founder of Insta360. A standout moment was the roundtable with unicorn founders, where these leaders exchanged bold ideas on scaling globally from Asia, a region rapidly emerging as the heartbeat of next-gen innovation. Building on that momentum, the two-day Founder Talk featured over 30 trailblazing founders driving breakthroughs in AI, robotics, consumer tech, and sustainability. The stage also welcomed over 25 rising stars at the Gen Z Founder Forum and Gen Z Awards Ceremony, where young innovators showcased tech-driven solutions to global challenges. From unicorn visionaries to next-generation disruptors, BEYOND Expo celebrated the full spectrum of entrepreneurial ambition shaping the future of Asia and beyond. Media Day Previewed BEYOND Expo 2025's Innovation Held ahead of the main exhibition, the Media Day welcomed Beyond Expo product showcases, Media Day facilitated meaningful exchanges between innovators and the global press, setting the stage for a high-impact expo with worldwide reach. A showcase for the tech-inspired products of the future BEYOND Expo showcased over 1,000 high-tech products, targeting daily lifestyle and sustainability solutions. These included biodegradable materials, enhanced earphones and speakers, smart eyewear, healthy food, humanoids, medical devices, robotic pets, sleeping aids, and future mobility solutions. B2B applications included AI-reality-inspired software, medical devices, energy-saving and industrial robots. Unmatched B2B Engagement and Industry Matchmaking For the first time, BEYOND Expo hosted multiple on-site business matchmaking sessions over three days, connecting key industry players. Major corporations such as China State Construction International, China Taiping, Sands China, CATL, Tokyu Land Corporation, BMW Group, Sony, Makuake, Mitsubishi Estate, and Panasonic participated, signaling strong demand for real-time, high-value engagement between corporates and innovators. These sessions provided both sides with an efficient platform to identify strategic partners and explore collaborative opportunities. International Delegations and Buyer Groups Expand Global Reach This year also saw the participation of numerous international delegations and 'buyer groups,' further amplifying BEYOND Expo's reach. Representatives from Deloitte China, BMW Group, Japanese buyer groups, Western crowdfunding platform executives, and prominent overseas influencers all engaged with exhibitors, many of whom reported valuable feedback and new partnership leads. BEYOND Expo was positioned as a global gateway for companies aiming to scale across Asia and beyond, while spotlighting the region's confidence and capacity in innovation. Backing the Region's Boldest Innovators BEYOND Expo further strengthened its commitment to supporting emerging companies with expanded programming tailored for startups. At the heart of Growth Park, a newly launched multi-purpose stage served as a high-impact arena for product unveilings, startup-focused events, and strategic partnership announcements. The Demo Stage, a headline feature of this space, gave rising tech companies the chance to debut their latest innovations in front of a global audience, including investors, media, and industry leaders. After Hours: Where Innovation Met Entertainment As day turned to night, BEYOND Expo 2025 transformed into a vibrant celebration where technology and culture seamlessly converged. Each evening featured exclusive events that blended immersive entertainment with meaningful networking opportunities. From Welcome Night and Gala Dinner to dynamic pool parties energized by live DJs, an electrifying performance by Jax Jones, and the breathtaking Cirque Le Soir circus spectacle, BEYOND Expo offered unforgettable experiences that extended the spirit of innovation well beyond the conference halls. BEYOND Expo 2025 Partners BEYOND Expo 2025 was made possible with the generous support of Strategic Partners China State Construction International Holdings Limited and China Taiping; Platinum Partners Taobao 88VIP and Macau Pass | MPay; Gold Partner Nam Kwong (Group) Company Limited; Sustainability Partner the Zayed Sustainability Prize; and Venue Partner Sands China Ltd. Additional partners included Asian Family Legacy Foundation, ChainNeXT, Design School of Hunan University, Founders Breakfast, Greenwich Economic Forum, GWA, MAP, INNOBAKER, IESt, Lushan Laboratory, ReGACY Innovation Group, RMI, Sherewires, SIEF, TNGlobal, wteam, and yehyehyeh. A full list of participating companies can be found here: BEYOND EXPO 2025 About BEYOND Expo The BEYOND International Technology Innovation Expo (BEYOND Expo) is Asia's leading annual technology event. Serving as a dynamic platform since 2021, BEYOND Expo not only showcases global technological innovations but also provides a unique opportunity to foster innovation upgrades across diverse industries and regions. BEYOND Expo has attracted participation from Asia's Fortune 500 companies, multinational corporations, unicorn companies, and emerging startups. Through a multifaceted approach involving expos, summits, and various activities, BEYOND Expo has successfully cultivated an innovative ecosystem, propelling collective development in the Asia-Pacific region and the global technology innovation industry.


New Straits Times
a day ago
- New Straits Times
Australia seeks stronger trade ties after 'unjustified' US tariffs
SYDNEY: Australia will push to expand free trade agreements with other countries to reduce its reliance on the United States, Trade Minister Don Farrell said Sunday, slamming President Donald Trump's "unjustified" tariffs. Australia is a close US ally but has been slugged with a blanket 10 per cent tariff on goods exported to the United States, rising to 50 per cent on steel and aluminium, as part of Trump's sweeping global duties. "I'm hopeful that those countries around the world who do believe in free and fair trade can reach an agreement to extend free trade agreements across the globe, so that irrespective of what the Americans might chose to do, we have a greater diversity of trading partners," Farrell told Sky News. He was speaking after talks last week in Paris with the World Trade Organisation, the Organisation for Economic Co-operation and Development (OECD) and other countries which he said had focused on preventing "protectionism" and encouraging free and fair trade. Trade between Australia and the United States is worth an estimated Aus$100 billion (US$65 billion) a year, with Australia buying more from the United States than it is selling, Farrell said. He said he had protested the duties last week to his US counterpart Jamieson Greer. "The position I've put to Jamieson Greer is that the tariffs that the United States have imposed on Australia are unjustified," Farrell said. "We want all of the tariffs removed, not just some of them." The European Union said last month it is seeking a defence partnership with Australia, as the bloc looks to forge a united international response to the Ukraine war and other global crises.